Shilpa Medicare announced that the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has issued final approval for grant of marketing authorization for OERIS (Ondansetron Extended-Release Injection, 100 mg/mL).
Market Samachar is a news aggregator. This article was originally published by Share Market Today. Tap the button above to read the full story on their site.